The nation of Zimbabwe has rejected a significant American health deal worth 367 million US dollars (£272m) spanning five years over the United States' request for sensitive data.
The decision became public following a official document dated December was disclosed, which showed President Emmerson Mnangagwa believed the arrangement was "unbalanced".
An official representative later stated that the US was requesting genetic material for scientific study and commercial purposes while was not willing to share the resulting advantages from any future treatments.
"We must now begin the difficult and regrettable process of winding down our support in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy indicated the US had donated over $1.9bn in health funding to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has called for more talks to find a deal agreeable to all parties so the country's critical HIV treatment initiative can be sustained.
Wider Background
This development comes after a comparable situation in Kenya, where a high court halted a related deal with the US following legal challenges were raised about the safety of citizens' health data.
After resuming the presidency last year, US President Donald Trump has reduced overseas assistance and shut down the key foreign aid agency.
USAID had managed aid for the US government, but Trump stated its expenditure was "inefficient" and his government was pursuing government-to-government agreements to enhance transparency and accountability.
As per reports, Sixteen African countries have so far signed similar agreements, representing over $18.3bn in new funding.
Specifics of the Declined Agreement
The funds for Zimbabwe would have supported "tackling HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"It is our view this collaboration might have yielded immense benefits for Zimbabwean communities, especially the 1.2 million currently receiving HIV treatment through US-supported initiatives," the Ambassador said.
However, official spokesman Nick Mangwana maintained the proposed deal was "asymmetrical".
"The proposal required Zimbabwe to surrender its genetic material and health information indefinitely, with no corresponding assurance of benefiting from any medical innovations – like new medicines or tests – that might result from that shared data," he stated.
"Effectively, our country would provide the raw materials for medical research with no assurance that the final treatments would be available to our population should a future health crisis emerge."
National Interest and Global Health
He also pointed out that the American exit from the global health body and its pursuit of one-on-one health agreements were disrupting structures previously set up through the international organization.
The spokesperson gave as an example its Pandemic Benefit-Sharing system created to manage future pandemics.
"This system is intended to ensure that when a country provides its data, the benefits – including vaccines and treatments – are distributed fairly, not monopolised solely by those with the funds to develop them."
Zimbabwe's reservations over the US deal "should not be misconstrued as anti-American sentiment," Mangwana stressed.
"We welcome continued dialogue with our American counterparts on how future co-operation could be arranged in a manner that respects the independence and dignity of each country."
Health Experts Response
A leading public health body stated it recognised the government's concerns, but suggested that talks must proceed since a large portion of the nation's Aids initiatives depended on international support.
"If technical issues exist, such as those involving data governance or implementation frameworks, these can frequently be addressed through technical clarification and negotiated safeguards," the group said.
The situation emphasises the ongoing debate between receiving crucial international aid and safeguarding local interests in an ever more data-driven world.